Immunovaccine closes $14.4 million bought deal offering with over-allotment option exercised in full

On February 15, 2018, Immunovaccine Inc. (TSX: IMV) (OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that it had closed its previously announced bought deal public offering of common shares, including exercise of the over-allotment option in full, raising gross proceeds of $14.375 million.

The offering was conducted by a syndicate of underwriters led by Echelon Wealth Partners Inc. and including National Bank Financial Inc. and Bloom Burton Securities Inc.

Gowling WLG advised the underwriters with a team that included Andre Poles, Josh Almario and Josh Rosen.